"Pfizer Inc. and Nektar Therapeutics said on Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product."
This is comforting.
"Pfizer updated the Exubera labeling to include a warning with safety information about lung cancer cases found in patients who used Exubera, which U.S. regulators approved in January 2006."
If you are ready to successfully lose the weight, go here.
Posts
No comments:
Post a Comment